Effect of interleukin-32γ on differentiation of osteoclasts from CD14+ monocytes

Arthritis and Rheumatism

Volumn 62, Issue 2, 2010, Pages 515-523

  Kim, Yong Gil ^a   Lee, Chang Keun ^a   Oh, Ji Seon ^a   Kim, Soo Hyun ^b   Kim, Kyoung A ^c   Yoo, Bin ^a  

^a University of Ulsan   (South Korea)

^b Konkuk University   (South Korea)

^c Asan Institute for Life Sciences   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 32GAMMA; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; UNCLASSIFIED DRUG; CATHEPSIN K; CTSK PROTEIN, HUMAN; IL32 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; NFATC1 PROTEIN, HUMAN; PROTEIN KINASE P60; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

CELL DIFFERENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERRATUM; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MONOCYTE; OSTEOARTHRITIS; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIOCYTE; SYNOVIUM; ARTICLE; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; GENETICS; IMMUNOLOGY; ISOMERISM; KNEE OSTEOARTHRITIS; METABOLISM; OSTEOLYSIS; PATHOLOGY; PHYSIOLOGY;

ANTIGENS, CD14; BONE RESORPTION; CATHEPSIN K; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; INTERLEUKINS; ISOMERISM; MONOCYTES; NFATC TRANSCRIPTION FACTORS; OSTEOARTHRITIS, KNEE; OSTEOCLASTS; OSTEOPROTEGERIN; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RANK LIGAND; RNA, MESSENGER; SYNOVIAL FLUID; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 75749117164     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27197     Document Type: Erratum

References (31)

1. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A 1990;87:7260-4.
2. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7:292-304.
3. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
4. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
5. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFα. Immunity 2005;22:131-42.
6. Netea MG, Lewis EC, Azam T, Joosten LA, Jaekal J, Bae SY, et al. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci U S A 2008;105: 3515-20.
7. Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S, et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 2006;18:233-40.
8. Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, et al. Identification of the most active interleukin-32 isoform. Immunology 2009;126:535-42.
9. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A 2006;103:3298-303.
10. Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, et al. Identification of the most active interleukin-32 isoform. Immunology 2009;126:535-42.
11. Kim KH, Shim JH, Seo EH, Cho MC, Kang JW, Kim SH, et al. Interleukin-32 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA. J Immunol Methods 2008;333: 38-50.
12. Itonaga I, Fujikawa Y, Sabokbar A, Murray DW, Athanasou NA. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 2000;192: 97-104.
13. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000;278:175-84.
14. Bai S, Zha J, Zhao H, Ross FP, Teitelbaum SL. Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclasts. J Biol Chem 2008;283:30861-7.
15. Yogo K, Ishida-Kitagawa N, Takeya T. Negative autoregulation of RANKL and c-Src signaling in osteoclasts. J Bone Miner Metab 2007;25:205-10.
16. Deal C. Future therapeutic targets in osteoporosis. Curr Opin Rheumatol 2009;21:380-5.
17. Mun SH, Kim JW, Nah SS, Ko NY, Lee JH, Kim JD, et al. Tumor necrosis factor α-induced interleukin-32 is positively regulated via the Syk/protein kinase Cδ/JNK pathway in rheumatoid synovial fibroblasts. Arthritis Rheum 2009;60:678-85.
18. Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002;4:281-9.
19. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996;11: 88-95.
20. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-603.
21. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
22. Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci 2007;1116:227-37.
23. Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci U S A 2006;103:3316-21.
24. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
25. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3: 168-77.
26. Jovanovic DV, Martel-Pelletier J, Di Battista JA, Mineau F, Jolicoeur FC, Benderdour M, et al. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum 2000;43:1134-44.
27. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophages. J Immunol 1998;160:3513-21.
28. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998;161:409-14.
29. Mabilleau G, Sabokbar A. Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS ONE 2009;4: e4173.
30. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001;44: 1003-12.
31. Sorensen MG, Henriksen K, Schaller S, Henriksen DB, Nielsen FC, Dziegiel MH, et al. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab 2007;25:36-45.